The role of tumor heterogeneity in immune-tumor interactions

Knoche, Shelby M.; Larson, Alaina C.; Sliker, Bailee H.; Poelaert, Brittany; Solheim, Joyce C.

doi:10.1007/s10555-021-09957-3

Cited by 19 publications

(10 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The tumor microenvironment is strongly correlated with tumor metastasis [ 38 ]. Infiltrated lymphocytes induce cancer cells to migrate into the vessels and then transfer to distant organs [ 39 ].…”

Section: Discussionmentioning

confidence: 99%

UHRF1 Induces Metastasis in Thyroid Cancer

Kuang

Lin

Liu

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Background. Ubiquitin-like with PHD and ring-finger domain 1 (UHRF1) has been defined as an oncogene in tumor cells. However, the role of UHRF1 in mediating metastasis in thyroid cancer remains unexplored. In this study, we aimed to investigate the metastatic function and the potential mechanisms of UHRF1 in thyroid cancer. Methods. Transwell assays were used to detect the metastatic capability of thyroid cancer. Dual-luciferase reporter assays were applied to examine the activation of transcription factors. Coimmunoprecipitation assays and immunofluorescence staining assays were used to elucidate the potential mechanisms of UHRF1 in promoting the metastasis of thyroid cancer. Results. In this study, we found that overexpression of UHRF1 promoted the metastasis of papillary thyroid cancer cells, and suppression of UHRF1 decreased the metastasis of anaplastic thyroid cancer cells. Regarding the signaling pathway in regulating metastasis, UHRF1 directly combined and activated the transcription factor c-Jun/AP-1 in the nucleus, subsequently increasing the transcription of IL-6 and MIF. Conclusion. Our results suggest that UHRF1 could induce the metastasis of thyroid cancer, and the potential signaling pathway might be that UHRF1 activates c-Jun/AP-1 to increase the expression of IL-6 and MIF. These findings provide a novel mechanism of UHRF1 and illustrate that UHRF1/AP-1 complex could be a potential therapeutic target for patients with thyroid cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

UHRF1 Induces Metastasis in Thyroid Cancer

Kuang

Lin

Liu

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…However, one of the big challenges for ex vivo subunit vaccines to overcome is the inherent tumor heterogeneity which exists in different tumor types and in each individual of the same tumor type, as the patient-specific tumor antigens are difficult to identify and isolate. 121,122 An effective immune response to tumors must be elicited by an optimal cancer vaccine, while normal host cells must be spared. 11,123 The strategy of in situ cancer vaccination for personalized therapy may be a promising alternative strategy to address this, in which cancer vaccines are generated in vivo without prior identification and isolation of TAAs.…”

Section: Polymeric Nps For In Situ Cancer Vaccinationmentioning

confidence: 99%

“…Conventional subunit antigen vaccine preparation employs antigen capturing ex vivo , but the traditional methods of enhancing the immune response by administering one or more selected antigens are unable to account for the tumor heterogeneity. 122,185 The above-mentioned methods based on specific chemotherapy and various exogenous stimuli can induce ICD in tumors by releasing TAAs and DAMPs, thereby forming in situ vaccination. Typically, TAAs and DAMPs are released from the apoptotic tumor tissue and then captured by DCs to induce their activation and maturation.…”

Section: Polymeric Nps For In Situ Cancer Vaccinationmentioning

confidence: 99%

Polymeric nanoparticle-based nanovaccines for cancer immunotherapy

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Cutting edge “omics” technologies combined to bioinformatic strategies allowed to study the ITH in more detail ( 51 ). Computer modeling of tumor/immune cell interactions including spatial and functional effects demonstrated that an increased cellular heterogeneity was associated with immune suppressive expression patterns ( 52 ) leading to a better survival of patients with low ITH ( 53 , 54 ). Recent findings suggest that the ITH is an essential genetic determinant of anti-tumor immune responses.…”

Section: Intratumoral Heterogeneity and Immune Responsementioning

confidence: 99%

Modulation of Lymphocyte Functions in the Microenvironment by Tumor Oncogenic Pathways

Seliger

Massa

2022

Front. Immunol.

View full text Add to dashboard Cite

Despite the broad application of different immunotherapeutic strategies for the treatment of solid as well as hematopoietic cancers, the efficacy of these therapies is still limited, with only a minority of patients having a long-term benefit resulting in an improved survival rate. In order to increase the response rates of patients to the currently available immunotherapies, a better understanding of the molecular mechanisms underlying the intrinsic and/or extrinsic resistance to treatment is required. There exist increasing evidences that activation of different oncogenic pathways as well as inactivation of tumor suppressor genes (TSG) in tumor cells inhibit the immune cell recognition and influegnce the composition of the tumor microenvironment (TME), thus leading to an impaired anti-tumoral immune response. A deeper understanding of the link between the tumor milieu and genomic alterations of TSGs and oncogenes is indispensable for the optimization of immunotherapies and to predict the patients’ response to these treatments. This review summarizes the role of different cancer-related, oncogene- and TSG-controlled pathways in the context of anti-tumoral immunity and response to different immunotherapies.

show abstract

The role of tumor heterogeneity in immune-tumor interactions

Cited by 19 publications

References 83 publications

UHRF1 Induces Metastasis in Thyroid Cancer

UHRF1 Induces Metastasis in Thyroid Cancer

Polymeric nanoparticle-based nanovaccines for cancer immunotherapy

Modulation of Lymphocyte Functions in the Microenvironment by Tumor Oncogenic Pathways

Contact Info

Product

Resources

About